Article · 4 May 2026
ArticlePublished 17 May 2024
Efficacy of Oxaliplatin, Fluorouracil and Calcium Folinate in Advanced Primary Liver Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This study seeks to elucidate the efficacy of oxaliplatin, fluorouracil and calcium folinate combined with hepatic arterial infusion chemotherapy, in patients with advanced primary liver cancer. In this study, 156 advanced primary liver cancer individuals who were treated in our hospital between July 2018 and July 2021 were selected among which 70 patients who received folinic acid/calcium folinate, fluorouracil and oxaliplatin regimen via conventional intravenous infusion were assigned as control group and 86 patients who received hepatic arterial infusion chemotherapy using the folinic acid/calcium folinate, fluorouracil and oxaliplatin regimen were included in the research group. The two groups were compared with respect to their curative effects, complication rate (nausea and vomiting, fatigue, fever, abnormal liver function and thrombocytopenia) and improvement of health status using Karnofsky performance scores. Similarly serum indices such as vascular endothelial growth factor, alpha-fetoprotein, cancer antigen 19-9 and 1 y overall survival were also evaluated. Significantly higher overall effectiveness, better improvement of health status (high Karnofsky performance scores) and fewer complications were found in the research group when compared with the control group; the post-treatment vascular endothelial growth factor, alphafetoprotein, cancer antigen 19-9 of the research group reduced statistically and were lower compared with the control group. Notably higher 1 y overall survival was determined in the research group. Therefore, hepatic arterial infusion chemotherapy using the folinic acid/calcium folinate, fluorouracil and oxaliplatin regimen is beneficial to improve the clinical outcomes of advanced primary liver cancer patients with a good preventive effect on the occurrence of complications, which can not only significantly improve patients’ health status, inhibit vascular endothelial growth factor, alpha-fetoprotein, cancer antigen 19-9 levels, but also significantly increase the 1 y overall survival of patients.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Indian Journal of Pharmaceutical Sciences.
Article · 21 Apr 2026
In silico molecular docking analysis of bioactive compounds from Kappaphycus alvarezii and Gracilaria debilis against BRCA1 protein
Article · 11 Mar 2026
Trimethoprim and Sulfamethoxazole-Loaded Nanoparticles Coated With Chitosan for Intranasal Delivery to Treat Cerebral Toxoplasmosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalIndian Journal of Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Minyan Fu”
- BylineArticles whose byline prints “K. W. He”
- BylineArticles whose byline prints “Hongxia Xu”
- BylineArticles whose byline prints “Cui Guo”
- BylineArticles whose byline prints “Huan Liu”
- BylineArticles whose byline prints “Huiping Li”